ORPOF (OSE Immunotherapeutics) Shares Outstanding (EOP): 22.42 Mil (As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $3.36
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Shares Outstanding (EOP)?

OSE Immunotherapeutics ORPOF 41 Shares Outstanding (EOP) is 22.42 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $3.36 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. OSE Immunotherapeutics's shares outstanding for the quarter that ended in Dec. 2025 was 22.42 Mil.

OSE Immunotherapeutics's quarterly shares outstanding increased from Jun. 2025 (22.42 Mil) to Dec. 2025 (22.42 Mil). It means OSE Immunotherapeutics issued new shares from Jun. 2025 to Dec. 2025 .

OSE Immunotherapeutics's annual shares outstanding increased from Dec. 2024 (21.90 Mil) to Dec. 2025 (22.42 Mil). It means OSE Immunotherapeutics issued new shares from Dec. 2024 to Dec. 2025 .


OSE Immunotherapeutics  (OTCPK:ORPOF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


OSE Immunotherapeutics Shares Outstanding (EOP) Related Terms


OSE Immunotherapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Shares Outstanding (EOP) Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.50 18.46 21.59 21.90 22.42

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.59 21.78 21.90 22.42 22.42

ORPOF vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, OSE Immunotherapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OSE Immunotherapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Shares Outstanding (EOP) falls into.


ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 22.42 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Shares Outstanding (EOP) of 22.42 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Shares Outstanding (EOP) too high?
OSE Immunotherapeutics' current Shares Outstanding (EOP) is 22.42 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Shares Outstanding (EOP) compare to VRTX and REGN?
OSE Immunotherapeutics' Shares Outstanding (EOP) of 22.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Shares Outstanding (EOP) is 22.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.43 — trading 31.8% above its estimated fair value. The current Shares Outstanding (EOP) is 22.42 Mil. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Shares Outstanding (EOP) is 22.42 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 31.8% above its estimated GF Value™ of $3.36. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Shares Outstanding (EOP): 22.42 Mil
  • GF Value™: $3.36 vs. price of $4.43 (31.8% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$3.36
GF Value